Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-07
1997-04-29
Dees, Jos e G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3144
Patent
active
056249322
ABSTRACT:
The present invention relates to a method of using a bioassay consisting of an electrophysiological method and a cell culture system of dorsal-root ganglion (DRG) neurons to screen and identify opioids with a high potential for use as "low- or non-addictive" analgesics. Another aspect of the invention relates to a specific group of opioid alkaloids and analogues thereof identified by the bioassay of the invention for the unique ability to activate only inhibitory, but not excitatory, opioid receptor function, for use as low- or non-addictive analgesics. Another aspect of the invention relates to the specific use of etorphine or dihydroetorphine of the opioid alkaloid family as low- or non-addictive analgesics and for the treatment of opioid addiction.
REFERENCES:
patent: 3763167 (1973-10-01), Hydro
patent: 4829056 (1989-05-01), Sugden
patent: 4891377 (1990-01-01), Shipman et al.
patent: 4906655 (1990-03-01), Horwell et al.
patent: 5192507 (1993-03-01), Taylor et al.
patent: 5472943 (1995-12-01), Crain et al.
Thorn-Gray and Levitt, Behavioral Neuroscience, 97(5) 768-778 (1983). Rat brain sites responsive to etorphine: Analgesia and catationia.
Williams et al, Proc Soc Exp Biol Med, 131(1) 97-100 (1969). Analegsic tolerance to etorphine and morphine in the mouse.
Blane, J Pharm Pharmac 19, 781-782 (1967). Absence of respiratory depression in the newborn rat after maternal administration of etorphine by sublingual route.
Shen and Crain, Brain Research, 531, 1-7 (1990). Cholera toxin-B subunit blocks excitatory effects of opioids on sensory neuron potentials indicating that GMI ganglioside may regulate Gs-linked opioid receptor functions.
Crain and Shen Trends in Pharmacological Sciences, 11(2), 1-7 (1990). Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons.
Bentley et al, Nature, 206, 102-103 (1965). Compounds possessing morphine-antagonizing or powerful analgesic properties.
Bentley and Hardy, Proc Chem Soc, p. 220 (1963). New potent analgesics in the morphine series.
Bentley and Hardy, J Am Chem Soc 89, 3281-3286 (1967). Novel analgesics and molecular rearrangements in the morphine-thebaine group III. Alcohols of the . . .
Blane and Robbin, Brit J Pharma Chemother 20, 252-253 (1970). Trial of etorphine bydrochloride (M99 Reckitt) in carcinoma pain: A preliminary report.
Blane et al, Brit J Pharma Chemother 30, 11-22 (1967). Action of etorphine hydrochloride (M99): A potent morphine-like agent.
Jasinski et al, Clin Pharma Ther 17, 267-272 (1975). Etorphine in man I. Subjective effects and suppression of morphine abstinence.
WHO Expert Committee on Dependence-producing Drugs, Fifteenth Report, p. 5 (1966).
Attali et al, Brain Research, 517, 182-188 (1990). Characterization of kappa opiate receptors in rat spinal cord-DRG cultrues and their regulation by chronic. . .
Cho et al, Proc Nat'l Acad Sci 80, 5176-5180 (1983). Isolation of opiate binding components of affinity chromatography and reconstruction of binding activity.
MacDonald et al, Science, 199, 1449-1451 (1978). Specific opiate induced depression of transmitter release from DRG cells in culture.
Qin and Huang, International Symposium on New Drug Research and Development, Beijing, China, Oct. 1991, Research advance and clinical application of highly potent dihydroetorphine hydrochloride.
Qin, 5th National Congress of Neuropharmacology, Mar. 1992. Progress in research of dihydroetorphine: From an analgesic to substitution agent in treatment of drug addiction.
Kosterlitz and Waterfield, Ann Rev Pharmacol 15, 29-47 (1975). In vitro models in the study of structure-activity relationships of narcotic analgesics.
Huang and Qin, Acta Pharmacologica Sinica 3, 9-13 (1982). Analgesic and other CNS depressive effects of dihydroetorphine.
Huang and Qin, Acta Pharmacologica Sinica 3, 81-84 (1982). Physical dependence of dihydroetorphine in mice and monkeys.
Cao et al, Chin J. Clin Pharmacol 6, 54-59 (1990). Drug dependence on dihydroetorphine.
Wang, Liu and Qin, Chin J Pharmacol and Toxicol 6, 36-40 (1992). Experimental therapeutic effects of dihydroetorphine in morphine-dependent rats and monkeys.
Huang et al, Acta Pharmacologica Sinica, 9, 308-312 (1988). Pharmacodynamics and pharmacokinetics of dihydroetorphine hydrochloride administered sublingually in mice and rats.
Wu and Sun, Chung Hua Chung Liu Tsa Chih 13, 64-67 (1991). Dihydroetorphine hydrochloride for moderate and severe cancer pain.
Crain Stanley M.
Gong Xiong-qi
Huang Mao
Qin Bo-yi
Shen Ke-Fei
Cebilak Mary C.
Dees Jos e G.
United Biomedical Inc.
LandOfFree
Method for identification of low/non-addictive opioid analgesics does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for identification of low/non-addictive opioid analgesics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for identification of low/non-addictive opioid analgesics will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-705928